Axonics Modulation Technologies, Inc (AXNX)

Etorro trading 970x250
Axonics Modulation Technologies, Inc (AXNX) Logo

About Axonics Modulation Technologies, Inc

Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company’s SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is headquartered in Irvine, California. Address: 26 Technology Drive, Irvine, CA, United States, 92618

Axonics Modulation Technologies, Inc News and around…

Latest news about Axonics Modulation Technologies, Inc (AXNX) common stock and company :

Axonics® to Report Third Quarter 2021 Financial Results on November 4
07 Oct, 2021 FinancialContent

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021.

US Patent Office Rejects Three More Axonics' Challenge To Medtronic Patents
23 Sep, 2021 FinancialContent

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed threeMedtronic plc(NYSE: ...

Axonics® Provides Additional Update on Inter Partes Review Proceedings
22 Sep, 2021 FinancialContent

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic patents that Axonics is contesting.

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Axonics® Announces Partial Decision on Inter Partes Review Proceedings
13 Sep, 2021 FinancialContent

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three of the six Medtronic patents that Axonics is contesting.

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
08 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Axonics Reaches Analyst Target Price
03 Sep, 2021 FinancialContent

In recent trading, shares of Axonics Inc (AXNX) have crossed above the average analyst 12-month target price of $75.33, changing hands for $77.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Axonics: Buy at the High?
02 Sep, 2021 FinancialContent

Axonics' stock price just hit its 52-week high, but its momentum means it's unlikely to last.

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Looking into Axonics Modulation Tech's Return on Capital Employed
30 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Axonics Modulation Tech (NASDAQ:AXNX) posted sales of $45.87 million. ...

Axonics® to Participate in Upcoming Investor Conferences
27 Aug, 2021 FinancialContent

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences:

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Monday
23 Aug, 2021 FinancialContent

Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market ...

Axonics Modulation Earns Relative Strength Rating Upgrade
18 Aug, 2021 FinancialContent

Axonics Modulation sees its Relative Strength Rating enter the elite 90-plus level.

Stocks That Hit 52-Week Highs On Tuesday
17 Aug, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) ...

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks Showing Improving Market Leadership: Axonics Modulation Earns 85 RS Rating
09 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for Axonics Modulation shows improving technical performance.

Did Axonics' (NASDAQ:AXNX) Share Price Deserve to Gain 58%?
09 Aug, 2021 Yahoo! Finance

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
05 Aug, 2021 Yahoo! Finance

Axonics (AXNX) delivered earnings and revenue surprises of -15.69% and 16.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Axonics® Reports Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021.

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Axonics Modulation Scores Relative Strength Rating Upgrade; Hits Key Benchmark
03 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for Axonics Modulation shows improving technical performance.

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
30 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Were Hedge Funds Right About Dumping Axonics, Inc. (AXNX)?
27 Jul, 2021 Yahoo! Finance

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 866 world-class investment firms that we track and now have access to the collective wisdom contained in […]

BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors
21 Jul, 2021 FinancialContent

BioVentrix announces Raymond W. Cohen as new chairman of the board, along with the appointment of two new board members.

Noteworthy Tuesday Option Activity: AXNX, EVRI, AIG
20 Jul, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axonics Inc (AXNX), where a total volume of 2,842 contracts has been traded thus far today, a contract volume which is representative of approximately 284,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.7% of AXNX's average daily trading volume over the past month, of 492,785 shares..

Axonics Modulation Technologies, Inc (AXNX) is a NASDAQ Common Stock listed in , ,

970x250